Trial Profile
Phase II Trial of Stereotactic Body Radiation Therapy in Combination With Nivolumab Plus Ipilimumab in Patients With Metastatic Renal Cell Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms RADVAX
- 29 Mar 2021 Status changed from active, no longer recruiting to completed.
- 19 Aug 2020 Planned End Date changed from 31 Jan 2020 to 31 Jan 2021.
- 19 Aug 2020 Status changed from recruiting to active, no longer recruiting.